News stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.0106404384874 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s analysis:

Several research firms recently weighed in on RTTR. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 19th. Roth Capital set a $2.00 price objective on Ritter Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, HC Wainwright dropped their price objective on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $2.92.

Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.30 on Monday. Ritter Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.14). sell-side analysts anticipate that Ritter Pharmaceuticals will post -0.66 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-ritter-pharmaceuticals-rttr-share-price.html.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.